These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37959261)

  • 41. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
    Cao WT; Huang R; Jiang KF; Qiao XH; Wang JJ; Fan YH; Xu Y
    World J Gastroenterol; 2021 Mar; 27(9):886-907. PubMed ID: 33727776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
    Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
    Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
    Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
    Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
    Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
    Christensen B; Hanauer SB; Erlich J; Kassim O; Gibson PR; Turner JR; Hart J; Rubin DT
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1557-1564.e1. PubMed ID: 28238954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.
    Boland K; Greener T; Kabakchiev B; Stempak J; Tessolini J; Li R; Soriano J; Croitoru K; Nguyen G; Steinhart AH; Weizman AV; Silverberg MS
    Inflamm Bowel Dis; 2020 Apr; 26(5):766-773. PubMed ID: 31676891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
    Boon GJ; Day AS; Mulder CJ; Gearry RB
    World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
    Lehtomäki J; Nikkonen A; Merras-Salmio L; Hiltunen P; Kolho KL
    Scand J Gastroenterol; 2022 Jan; 57(1):31-36. PubMed ID: 34546843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.
    Sirmai L; Pelletier AL; Gault N; Zallot C; Bouguen G; Bouchard D; Roland Nicaise P; Peyneau M; Sironneau S; Bittencourt MC; Petitcollin A; Fernandez P; Roblin X; Siproudhis L; Abramowitz L
    World J Gastroenterol; 2022 Mar; 28(9):961-972. PubMed ID: 35317057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse.
    Park J; Kang SJ; Yoon H; Park J; Oh HJ; Na HY; Lee HS; Shin CM; Park YS; Kim N; Lee DH
    Inflamm Bowel Dis; 2022 Nov; 28(11):1709-1716. PubMed ID: 35016209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease.
    Buffone E; Gupta S; Al Ibrahim B; Marshall JK; Halder S; Tse F; Albashir S; Morgan D; Lumb B; Armstrong D; Narula N
    J Clin Gastroenterol; 2022 Oct; 56(9):794-797. PubMed ID: 34753872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.
    Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP
    World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
    Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
    J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study.
    Wilson A; Choi B; Sey M; Ponich T; Beaton M; Kim RB
    BMC Gastroenterol; 2021 Feb; 21(1):77. PubMed ID: 33602145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
    Roblin X; Genin C; Nancey S; Williet N; Veyrard P; Boschetti G; Phelip JM; Berger AE; Killian M; Waeckel L; Flourie B; Paul S
    Inflamm Bowel Dis; 2022 May; 28(5):720-727. PubMed ID: 34405867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease.
    Szymanska E; Dadalski M; Grajkowska W; Szymanska S; Pronicki M; Kierkus J
    Prz Gastroenterol; 2017; 12(1):44-48. PubMed ID: 28337236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
    Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
    Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.
    Calvo Moya M; González Lama Y; Ruíz Antorán B; Omella Usieto I; El Hajra Martinez I; Santos Pérez E; Menchén Viso B; Matallana Royo V; González Partida I; de Lucas Tellez de Meneses R; Bella Castillo P; González Rodriguez M; Vera Mendoza MI
    Crohns Colitis 360; 2023 Jan; 5(1):otac051. PubMed ID: 36785555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.